Funding for this research was provided by:
Bayer Pharma, AG
Received: 25 September 2019
Revised: 26 March 2020
Accepted: 29 April 2020
First Online: 27 May 2020
Ethics approval and consent to participate
: All animal experiments were performed in accordance with relevant guidelines and regulations, and all mice were treated according to protocols approved by the Institutional Animal Care and Use Committee at UCSD; no human subjects were included in these experiments.
: Not applicable; no human subjects were included in these experiments.
: All data generated or analysed during this study are included in this published article (and the InternalRef removed files).
: This study was supported by Bayer, AG with study drug and research funding (to P.E.Z.). The authors declare there are no other competing interests.
: This study was supported by Bayer, AG with study drug and research funding (to P.E.Z.). This work was supported in part by a Cancer Prevention & Research Institute of Texas Proteomics & Metabolomics Core Facility Support Award (RP170005) (to S.H.) and an NCI Cancer Center Support Grant to the Antibody-based Proteomics Core/Shared Resource at Baylor College of Medicine (P30CA125123) (to S.H.).